{
  "docId": "019de515-1bf5-75fc-a19f-ef7a3323e229",
  "docSlug": "a43786f91ea3b101a0e62521077ddab4",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 14 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 14,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-1bf5-75fc-a19f-ef7a3323e229/4",
  "deckHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229",
  "deckJsonHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229.json",
  "deckAnchorHref": "/decks/019de515-1bf5-75fc-a19f-ef7a3323e229#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.21,
        "x": 0.28,
        "y": 0.3
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b71ede4-6477-4c71-8dad-ab9b14a4b9c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.21,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12e8ef55-aa7e-489e-9144-b208ef50c253",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.21,
        "x": 0.51,
        "y": 0.3
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14e143b9-0dbc-456f-82d0-3cff1baa4c88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.21,
        "x": 0.74,
        "y": 0.3
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db4e35ad-4063-4bc6-906a-55a25733a9d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.19,
        "x": 0.3,
        "y": 0.56
      },
      "kind": "list",
      "text": "No vaccine alternatives for prevention\nThere are no monoclonal antibodies authorized or approved for COVID-19 prevention or treatment in U.S. against circulating variants 4,5",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a2f5dba-8db3-4229-a087-0904e0417c23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.19,
        "x": 0.76,
        "y": 0.56
      },
      "kind": "list",
      "text": "Undervaccinated population\nAs of January 31, 2023, ~60% of population in the U.S. aged 65+ have not received the updated bivalent booster8",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73b05507-062b-4749-ba42-aab5b9c6aab4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.07,
        "y": 0.56
      },
      "kind": "list",
      "text": "Immunocompromised people are vulnerable to infection\nCDC estimates ~2.7% of U.S. population may be immunocompromised, approximately 8 million people 2,3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb7949f7-953e-4f9d-8694-ea8e91463b2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.19,
        "x": 0.53,
        "y": 0.56
      },
      "kind": "list",
      "text": "People at higher risk of hospitalization and death\n~56 million people in U.S. aged 65+6\n116 million adults in U.S. with comorbidities7",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d242c11a-22e9-4d6c-af1b-780a872cda70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Vaccination and increased levels of population immunity have reduced SARS-CoV-2 associated diseases and mortality; however, significant unmet medical need remains",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d495c97-1a9f-4cf5-b907-335ee3f8b4a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.59,
        "x": 0.05,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "VYD222 is an investigational product candidate not approved for use in any country. The safety and efficacy of VYD222 have not been established.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68416ca8-41ed-49e9-bbbe-3e11611bccea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.87,
        "x": 0.05,
        "y": 0.81
      },
      "kind": "source-note",
      "text": "1. https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-leading-cause-of-death-ranking/\n2. Harpaz R, et al. Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016;316(23):2547-2548.\n3. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html\n4. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region#:-:text=FDA%20Announces%20Bebtelovimab%20is%20Not%20Currently%20Authorized%20in%20Any%20US%20Region,-Share&text=%5B11%2F30%2F2022%5D,to%20neutralize%20Omicron%20subvariants%20BQ.\n5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us#:-:text=Based%20on%20this%20revision%2C%20Evusheld,SARS%2DCoV%2D2%20variants.\n6. www.census.gov 1/31/2023\n7. www.census.gov 1/31/23 and https://wwwnc.cdc.gov/eid/article/26/8/20-0679_article\n8. https://www.cnn.com/2022/12/16/health/bivalent-boosters-vaccine-effectiveness-studies/index.html",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7125012-c5ac-447b-b7bf-47d7909f7715",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.44,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aa2a2c6-49d7-4bb4-862d-924f3fd2567b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3de801da-5bdf-4c11-97ed-d3fb27d3c6d5",
      "evidence": "The slide uses a list/bullet format to present key points about the vulnerability of immunocompromised people and the undervaccinated population.",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "5a4203f3-4753-4981-9ddb-0819dd030f5b",
      "evidence": "The slide presents a clear problem statement about COVID-19 being the third leading cause of death in the U.S., highlighting the unmet medical need.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "288e8599-a6b1-4102-93ca-9e91cdaafd9c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem Identification",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slide 4 states 'COVID IS THIRD LEADING CAUSE OF DEATH IN THE U.S.'",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 5,
      "from": 4,
      "beatId": "ccab2ada-1cc8-4c81-9cde-c0f1b2528cce",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitation",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 4 and 5 agitate the problem by highlighting the need for better solutions.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d3def03c-312d-4999-8437-44a76f4d6117",
      "evidence": "The loop is used to emphasize the need for better COVID-19 treatments.",
      "position": 0,
      "objective": "Highlight the cost of not acting or current limitations",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}